Anika Therapeutics (ANIK)
Market Price (5/25/2026): $14.86 | Market Cap: $201.1 MilSector: Health Care | Industry: Pharmaceuticals
Anika Therapeutics (ANIK)
Market Price (5/25/2026): $14.86Market Cap: $201.1 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -123% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 31x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.6% Key risksANIK key risks include [1] the pivotal clinical trial failure for its key Hyalofast product and a related securities fraud investigation, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -82%, 3Y Excs Rtn is -123% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -12 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -11% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 31x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.4% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.6% |
| Key risksANIK key risks include [1] the pivotal clinical trial failure for its key Hyalofast product and a related securities fraud investigation, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Anika Therapeutics (ANIK) stock has gained about 60% since 1/31/2026 because of the following key factors:
1. Exceptional Q1 2026 Financial Performance and Operational Execution.
Anika Therapeutics significantly exceeded analyst expectations in the first quarter of 2026, reporting a 13% year-over-year revenue increase to $29.6 million, surpassing analyst forecasts of $28.11 million. The company's adjusted earnings per share (EPS) of $0.27 represented a substantial 250% surprise compared to analyst predictions of -$0.18. This strong financial showing was largely driven by an 8.1 percentage point expansion in gross margin, reaching 64.2% from 56.1% in Q1 2025, and a significant improvement in adjusted EBITDA to $4.3 million from $0.1 million in the prior-year period, reflecting successful operational execution and margin improvement initiatives.
2. Strong Commercial Channel Growth and Product Momentum.
The company demonstrated robust growth within its commercial channel, with revenue increasing by 12% year-over-year to $12.6 million in Q1 2026. A key contributor to this growth was the continued market penetration of its rotator cuff repair solution, Integrity, which saw U.S. procedures rise by 35% year-over-year and generated nearly $2 million in quarterly revenue.
Show more
1. Exceptional Q1 2026 Financial Performance and Operational Execution.
Anika Therapeutics significantly exceeded analyst expectations in the first quarter of 2026, reporting a 13% year-over-year revenue increase to $29.6 million, surpassing analyst forecasts of $28.11 million. The company's adjusted earnings per share (EPS) of $0.27 represented a substantial 250% surprise compared to analyst predictions of -$0.18. This strong financial showing was largely driven by an 8.1 percentage point expansion in gross margin, reaching 64.2% from 56.1% in Q1 2025, and a significant improvement in adjusted EBITDA to $4.3 million from $0.1 million in the prior-year period, reflecting successful operational execution and margin improvement initiatives.
2. Strong Commercial Channel Growth and Product Momentum.
The company demonstrated robust growth within its commercial channel, with revenue increasing by 12% year-over-year to $12.6 million in Q1 2026. A key contributor to this growth was the continued market penetration of its rotator cuff repair solution, Integrity, which saw U.S. procedures rise by 35% year-over-year and generated nearly $2 million in quarterly revenue.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 61.0% change in ANIK stock from 1/31/2026 to 5/25/2026 was primarily driven by a 46.6% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.23 | 14.86 | 61.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 113 | 116 | 3.1% |
| P/S Multiple | 1.2 | 1.7 | 46.6% |
| Shares Outstanding (Mil) | 14 | 14 | 6.6% |
| Cumulative Contribution | 61.0% |
Market Drivers
1/31/2026 to 5/25/2026| Return | Correlation | |
|---|---|---|
| ANIK | 61.2% | |
| Market (SPY) | 8.1% | 17.5% |
| Sector (XLV) | -2.7% | 30.3% |
Fundamental Drivers
The 52.4% change in ANIK stock from 10/31/2025 to 5/25/2026 was primarily driven by a 41.5% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.75 | 14.86 | 52.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 115 | 116 | 1.5% |
| P/S Multiple | 1.2 | 1.7 | 41.5% |
| Shares Outstanding (Mil) | 14 | 14 | 6.2% |
| Cumulative Contribution | 52.4% |
Market Drivers
10/31/2025 to 5/25/2026| Return | Correlation | |
|---|---|---|
| ANIK | 52.6% | |
| Market (SPY) | 9.9% | 18.8% |
| Sector (XLV) | 4.8% | 30.0% |
Fundamental Drivers
The 2.3% change in ANIK stock from 4/30/2025 to 5/25/2026 was primarily driven by a 7.7% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302025 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.53 | 14.86 | 2.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 120 | 116 | -3.0% |
| P/S Multiple | 1.8 | 1.7 | -2.1% |
| Shares Outstanding (Mil) | 15 | 14 | 7.7% |
| Cumulative Contribution | 2.3% |
Market Drivers
4/30/2025 to 5/25/2026| Return | Correlation | |
|---|---|---|
| ANIK | 2.4% | |
| Market (SPY) | 36.0% | 23.3% |
| Sector (XLV) | 8.6% | 28.7% |
Fundamental Drivers
The -42.1% change in ANIK stock from 4/30/2023 to 5/25/2026 was primarily driven by a -47.5% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5252026 | Change |
|---|---|---|---|
| Stock Price ($) | 25.66 | 14.86 | -42.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 114 | 116 | 2.1% |
| P/S Multiple | 3.3 | 1.7 | -47.5% |
| Shares Outstanding (Mil) | 15 | 14 | 8.0% |
| Cumulative Contribution | -42.1% |
Market Drivers
4/30/2023 to 5/25/2026| Return | Correlation | |
|---|---|---|
| ANIK | -42.0% | |
| Market (SPY) | 86.3% | 26.6% |
| Sector (XLV) | 18.0% | 26.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ANIK Return | -21% | -17% | -23% | -27% | -42% | 56% | -67% |
| Peers Return | -10% | -23% | 16% | 27% | -2% | -1% | -1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| ANIK Win Rate | 25% | 58% | 58% | 50% | 50% | 60% | |
| Peers Win Rate | 46% | 45% | 53% | 52% | 47% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ANIK Max Drawdown | -29% | -44% | -47% | -44% | -55% | -23% | |
| Peers Max Drawdown | -25% | -43% | -38% | -20% | -28% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ZBH, SYK, JNJ, BVS, OFIX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)
How Low Can It Go
| Event | ANIK | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.5% | -9.5% |
| % Gain to Breakeven | 46.0% | 10.5% |
| Time to Breakeven | 133 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.4% | -33.7% |
| % Gain to Breakeven | 90.2% | 50.9% |
| Time to Breakeven | 275 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.0% | -19.2% |
| % Gain to Breakeven | 39.0% | 23.8% |
| Time to Breakeven | 213 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -11.4% | -3.7% |
| % Gain to Breakeven | 12.8% | 3.9% |
| Time to Breakeven | 28 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -13.8% | -12.2% |
| % Gain to Breakeven | 15.9% | 13.9% |
| Time to Breakeven | 29 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -25.4% | -6.8% |
| % Gain to Breakeven | 34.0% | 7.3% |
| Time to Breakeven | 38 days | 15 days |
In The Past
Anika Therapeutics's stock fell -4.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ANIK | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -31.5% | -9.5% |
| % Gain to Breakeven | 46.0% | 10.5% |
| Time to Breakeven | 133 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -47.4% | -33.7% |
| % Gain to Breakeven | 90.2% | 50.9% |
| Time to Breakeven | 275 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.0% | -19.2% |
| % Gain to Breakeven | 39.0% | 23.8% |
| Time to Breakeven | 213 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -25.4% | -6.8% |
| % Gain to Breakeven | 34.0% | 7.3% |
| Time to Breakeven | 38 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -25.4% | -17.9% |
| % Gain to Breakeven | 34.0% | 21.8% |
| Time to Breakeven | 29 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -23.8% | -15.4% |
| % Gain to Breakeven | 31.3% | 18.2% |
| Time to Breakeven | 206 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -81.0% | -53.4% |
| % Gain to Breakeven | 427.7% | 114.4% |
| Time to Breakeven | 1203 days | 1085 days |
In The Past
Anika Therapeutics's stock fell -4.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 4.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Anika Therapeutics (ANIK)
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies for Anika Therapeutics (ANIK):
- Zimmer Biomet for joint preservation with natural, injectable solutions.
- Amgen for hyaluronic acid-based therapies, targeting joint health and other medical applications.
- A specialized Medtronic focused on hyaluronic acid technology for joint pain and tissue repair.
AI Analysis | Feedback
```html- Osteoarthritis (OA) Pain Management Products: This family includes products like Monovisc, Orthovisc, Cingal, and Hyvisc, indicated for pain relief from osteoarthritis conditions.
- Joint Preservation and Restoration Products: This category comprises bone preserving joint technologies, sports medicine soft tissue repair solutions, and orthopedic regenerative solutions.
- Non-Orthopedic HA-based Products: These are hyaluronic acid-based products for various applications outside orthopedics, such as adhesion barriers, advanced wound care, ophthalmic uses, and ear, nose, and throat treatments.
AI Analysis | Feedback
The provided background information does not name specific major customer companies for Anika Therapeutics. However, based on the description of its products (medical devices, treatments for osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving technologies), Anika Therapeutics primarily sells to other companies and organizations within the healthcare sector.
The major categories of its business customers include:
- Hospitals and Surgical Centers: These institutions utilize Anika's orthopedic, soft tissue repair, and regenerative solutions for surgical procedures and patient care.
- Clinics and Physician Offices: Particularly orthopedic clinics, rheumatology practices, and sports medicine practices, which administer Anika's OA pain management injections and other related treatments.
- Healthcare Distributors and Group Purchasing Organizations (GPOs): These intermediaries facilitate the sale and distribution of Anika's products to various healthcare facilities and systems.
AI Analysis | Feedback
nullAI Analysis | Feedback
Steve Griffin, President and Chief Executive Officer Mr. Griffin was appointed President and Chief Executive Officer of Anika Therapeutics, effective February 1, 2026, and also continues to act as the company's principal financial officer. He joined Anika in June 2024 as Executive Vice President, Chief Financial Officer, and Chief Operating Officer, and was elevated to COO in April 2025. Prior to Anika, he served as Senior Vice President and Chief Financial Officer at VSE Corporation, where he was instrumental in executing a strategic transformation through organic growth, six acquisitions, and two divestitures. Before his tenure at VSE, Mr. Griffin spent over a decade at General Electric in various finance leadership roles, including Corporate Audit, Financial Planning and Analysis, and Divisional CFO roles across GE Healthcare, GE Aerospace, and GE Power. He is a graduate of GE's financial management program. David Colleran, Executive Vice President, General Counsel and Corporate Secretary David Colleran serves as Executive Vice President, General Counsel, and Corporate Secretary for Anika Therapeutics. Ian McLeod, Vice President, Chief Accounting Officer and Treasurer Ian McLeod holds the position of Vice President, Chief Accounting Officer, and Treasurer at Anika Therapeutics. Mira Leiwant, Senior Vice President, Regulatory, Quality and Clinical Affairs Mira Leiwant is the Senior Vice President of Regulatory, Quality, and Clinical Affairs at Anika Therapeutics. Dawn Wilson, Vice President, Research and Development Dawn Wilson serves as the Vice President of Research and Development for Anika Therapeutics.AI Analysis | Feedback
Key Business Risks for Anika Therapeutics (ANIK)
-
Regulatory Hurdles and Product Development Risks: Anika Therapeutics faces significant risks related to the development and regulatory approval of its pipeline products, such as Cingal and Hyalofast. Delays or failures in obtaining FDA or international regulatory approvals, and challenges in clinical trials, could materially impact the company's competitive position and future financial results. For example, Hyalofast's U.S. Phase III trial did not meet its pre-specified co-primary endpoints, and the FDA has issued a deficiency letter regarding its PMA submission. Similarly, Cingal has faced a longer-than-expected pathway to commercialization in the United States, requiring additional bioequivalence work.
-
Competition and Pricing Pressure: The company operates in a highly competitive medical technology sector, particularly in its core areas of osteoarthritis (OA) pain management and regenerative solutions. Anika faces intense competition from larger, established players, which can negatively affect its market share and pricing power. This is evident in ongoing pricing pressures in the U.S. OA pain market, specifically within the OEM channel, which has led to projected declines in OEM channel revenue for products like Monovisc and Orthovisc due to revised pricing from its commercial partner.
-
Customer Concentration and Dependence on Strategic Partners: A substantial portion of Anika Therapeutics' revenue is derived from a limited number of customers and is heavily dependent on marketing and distribution partners. For instance, J&J MedTech accounted for 50% of revenue in 2025 and 57% in 2024. The loss of such key customers or changes in strategic partnership arrangements, particularly in the OEM channel where a commercial partner influences sales, marketing, and pricing, could materially and adversely affect the company's business, financial condition, and results of operations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Anika Therapeutics operates in several key orthopedic care markets, including osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone-preserving joint technologies. The addressable markets for these main product areas are substantial both globally and within the United States. For **OA pain management**, the global osteoarthritis pain drugs market was valued at approximately USD 9.52 billion in 2025 and is projected to reach USD 14.33 billion by 2032. Another estimate places the global osteoarthritis treatment market at US$ 9.8 billion in 2025, with a projection to reach US$ 15.3 billion by 2032. In the United States, the osteoarthritis treatment market size was approximately USD 19 billion in 2023. In the realm of **regenerative solutions**, the global orthopedic regenerative surgical products market was estimated at USD 4.14 billion in 2022 and is expected to grow to USD 5.63 billion by 2030. More recent projections indicate the global market size at USD 4.56 billion in 2025, anticipated to increase to approximately USD 8.17 billion by 2035. North America is a dominant region within this market, accounting for over 42% of the revenue share in 2025. The **soft tissue repair** market globally was valued at USD 14.65 billion in 2023 and is projected to reach USD 22.89 billion by 2030. Another report valued the global soft tissue repair market at USD 15.51 billion in 2025, with an estimated growth to USD 20.33 billion by 2031. North America held a significant share of this market, with 46.25% in 2023, and the U.S. market alone dominated North America with an 89.3% revenue share in the same year. For **bone-preserving joint technologies**, which encompasses joint reconstruction and bone regeneration, the global joint reconstruction devices market was valued at USD 28.91 billion in 2024 and is expected to reach USD 41.23 billion by 2033. The United States alone represented a significant portion of this market, with a value of USD 12.54 billion in 2024, projected to reach USD 13 billion in 2025. The global bone regeneration material market size was calculated at USD 3.85 billion in 2024 and is projected to reach approximately USD 8.87 billion by 2034. Additionally, the global bone replacement market is expected to be around USD 29.9 billion by 2033, up from USD 17.2 billion in 2023. The global bone grafts and substitutes market was estimated at USD 3.34 billion in 2025 and is projected to reach USD 5.50 billion by 2033. North America held the largest share of the bone grafts and substitutes market with 41.96% in 2025.AI Analysis | Feedback
Anika Therapeutics (ANIK) is expected to drive future revenue growth over the next two to three years through several key initiatives and product advancements:
- Growth in the Commercial Channel, especially International OA Pain Management: Anika anticipates continued strong performance from its commercial channel, particularly in international osteoarthritis (OA) pain management. Products such as Monovisc, Orthovisc, and Cingal are expected to maintain and expand market share through geographic expansion. The commercial channel has consistently delivered robust growth, with a 25% increase in Q4 2024 and 17% for the full year 2024, and 18% in Q1 2025, driven by international OA pain management. The company expects commercial channel revenue to grow 12% to 18% year-over-year in 2025, and 10% to 20% in 2026.
- Increased Adoption and Expansion of the Integrity™ Implant System: The Integrity Implant System is a significant driver within Anika's regenerative solutions portfolio. It has demonstrated consistent sequential growth, with procedures and revenue more than doubling in 2025. The company highlights its expanding surgeon adoption and market penetration as key growth factors.
- U.S. Launch and Adoption of Hyalofast: Anika is actively progressing towards the U.S. launch of Hyalofast. Regulatory milestones, including MDR approval and the filing of PMA modules, have been achieved, with the third and final PMA module on track for submission in the second half of 2025. A U.S. launch is anticipated in 2026, with an expected revenue contribution in 2027.
- U.S. NDA Filing and Potential Launch of Cingal: Anika has received formal written feedback from the FDA regarding Cingal, which has cleared the path for its New Drug Application (NDA) filing following the completion of a bioequivalence bridging study. The successful completion of this study and subsequent NDA filing would open the door for a potential U.S. launch, contributing to future revenue.
- Strategic Realignment and Focus on Core Orthopedic Markets: The company has strategically refocused its resources on high-opportunity areas within orthopedics, specifically OA pain management and regenerative solutions. This includes the divestiture of non-core assets like Arthrosurface and Parcus Medical to streamline operations and enhance returns. This sharpened focus is expected to improve revenue diversification and concentrate efforts on more profitable growth areas.
AI Analysis | Feedback
Share Repurchases
- Anika Therapeutics initiated a stock repurchase program in May 2024, utilizing $10.9 million to repurchase shares.
- A $50 million share repurchase program was authorized in May 2019, comprising $30 million through an accelerated share repurchase (ASR) program and $20 million on the open market, with completion anticipated by the second quarter of 2020.
Share Issuance
- Anika Therapeutics had approximately 14.18 million shares of common stock outstanding as of March 6, 2025.
- The company reported 14.85 million shares of common stock outstanding as of March 6, 2024.
Outbound Investments
- In October 2024, Anika Therapeutics announced a strategic shift to concentrate on OA Pain Management and Regenerative Solutions, leading to the sale of Arthrosurface Incorporated on October 31, 2024.
- The divestiture of Parcus Medical, LLC to Medacta Group SA was completed on March 7, 2025, for an undisclosed cash consideration.
Capital Expenditures
- Anika Therapeutics' capital expenditures for the full year 2025 amounted to $6.8 million.
- In Q4 2025, the company invested $648,000 in capital expenditures.
- The company plans to continue investing in research and development for new products and clinical trials related to its hyaluronic acid-based technology.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Anika Therapeutics Earnings Notes | 12/16/2025 | |
| How Low Can Anika Therapeutics Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ANIK.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 50.43 |
| Mkt Cap | 8.7 |
| Rev LTM | 4,617 |
| Op Inc LTM | 736 |
| FCF LTM | 735 |
| FCF 3Y Avg | 652 |
| CFO LTM | 888 |
| CFO 3Y Avg | 828 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 5.1% |
| Rev Chg Q | 8.0% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 16.5% |
| Op Inc Chg 3Y Avg | 10.4% |
| Op Mgn LTM | 13.6% |
| Op Mgn 3Y Avg | 12.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 18.9% |
| CFO/Rev 3Y Avg | 13.3% |
| FCF/Rev LTM | 16.9% |
| FCF/Rev 3Y Avg | 11.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 8.7 |
| P/S | 1.9 |
| P/Op Inc | 11.1 |
| P/EBIT | 12.5 |
| P/E | 21.9 |
| P/CFO | 17.6 |
| Total Yield | 4.2% |
| Dividend Yield | 0.5% |
| FCF Yield 3Y Avg | 3.4% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -4.6% |
| 3M Rtn | -8.7% |
| 6M Rtn | 3.8% |
| 12M Rtn | 14.5% |
| 3Y Rtn | -5.6% |
| 1M Excs Rtn | -9.5% |
| 3M Excs Rtn | -18.0% |
| 6M Excs Rtn | -5.7% |
| 12M Excs Rtn | -17.6% |
| 3Y Excs Rtn | -89.7% |
Price Behavior
Price Behavior
| Market Price | $14.88 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 05/04/1993 | |
| Distance from 52W High | -7.0% | |
| 50 Days | 200 Days | |
| DMA Price | $14.78 | $11.06 |
| DMA Trend | up | up |
| Distance from DMA | 0.7% | 34.5% |
| 3M | 1YR | |
| Volatility | 75.5% | 57.7% |
| Downside Capture | 142.87 | 170.61 |
| Upside Capture | 209.65 | 150.99 |
| Correlation (SPY) | 19.4% | 22.9% |
ANIK Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.36 | 1.35 | 0.72 | 0.65 | 1.10 | 0.82 |
| Up Beta | 0.78 | 0.89 | 0.76 | 1.23 | 1.20 | 0.62 |
| Down Beta | 3.76 | -0.11 | 1.19 | 0.47 | -0.31 | 0.72 |
| Up Capture | 164% | 202% | 189% | 114% | 167% | 58% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 12 | 21 | 36 | 65 | 126 | 365 |
| Down Capture | 737% | 166% | -78% | -10% | 149% | 106% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 10 | 22 | 28 | 59 | 121 | 370 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIK | |
|---|---|---|---|---|
| ANIK | 32.4% | 57.5% | 0.72 | - |
| Sector ETF (XLV) | 16.0% | 14.5% | 0.80 | 27.2% |
| Equity (SPY) | 29.5% | 12.0% | 1.86 | 22.3% |
| Gold (GLD) | 35.5% | 26.8% | 1.11 | 13.7% |
| Commodities (DBC) | 42.9% | 18.7% | 1.77 | -17.4% |
| Real Estate (VNQ) | 15.2% | 13.1% | 0.82 | 26.6% |
| Bitcoin (BTCUSD) | -31.3% | 41.8% | -0.78 | 13.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIK | |
|---|---|---|---|---|
| ANIK | -18.4% | 44.6% | -0.30 | - |
| Sector ETF (XLV) | 5.7% | 14.7% | 0.21 | 28.7% |
| Equity (SPY) | 14.0% | 17.0% | 0.64 | 31.3% |
| Gold (GLD) | 18.8% | 18.0% | 0.85 | 10.6% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 2.7% |
| Real Estate (VNQ) | 3.8% | 18.8% | 0.10 | 29.2% |
| Bitcoin (BTCUSD) | 11.6% | 55.3% | 0.41 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ANIK | |
|---|---|---|---|---|
| ANIK | -9.9% | 47.3% | -0.03 | - |
| Sector ETF (XLV) | 9.9% | 16.5% | 0.49 | 31.0% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 33.0% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 6.0% |
| Commodities (DBC) | 7.8% | 17.9% | 0.35 | 9.9% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 29.2% |
| Bitcoin (BTCUSD) | 66.7% | 66.9% | 1.06 | 13.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 16.9% | 31.3% | 34.8% |
| 11/5/2025 | 2.3% | 5.2% | -0.3% |
| 7/30/2025 | -27.4% | -25.2% | -17.7% |
| 3/12/2025 | -11.1% | -6.8% | -20.5% |
| 10/31/2024 | -30.7% | -30.0% | -28.2% |
| 8/8/2024 | 0.0% | -0.5% | -5.5% |
| 3/13/2024 | -3.4% | 0.7% | -1.6% |
| 11/2/2023 | 11.2% | 7.4% | 19.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 6 | 7 |
| # Negative | 13 | 13 | 12 |
| Median Positive | 6.0% | 6.3% | 7.9% |
| Median Negative | -9.2% | -9.8% | -8.2% |
| Max Positive | 16.9% | 31.3% | 34.8% |
| Max Negative | -30.7% | -30.0% | -28.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/30/2026 | 10-Q |
| 12/31/2025 | 03/03/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/15/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Company Revenue | 114.00 Mil | 118.25 Mil | 122.50 Mil | 0 | Affirmed | Guidance: 118.25 Mil for 2026 | |
| 2026 Commercial Channel Revenue | 53.00 Mil | 55.50 Mil | 58.00 Mil | 0 | Affirmed | Guidance: 55.50 Mil for 2026 | |
| 2026 OEM Channel Revenue | 61.00 Mil | 62.75 Mil | 64.50 Mil | 0 | Affirmed | Guidance: 62.75 Mil for 2026 | |
| 2026 Adjusted EBITDA as a percent of revenue | 0.05 | 0.07 | 0.1 | 0 | 0 | Affirmed | Guidance: 0.07 for 2026 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.